» Articles » PMID: 6181515

Anti-idiotypic Route to Anti-acetylcholine Receptor Antibodies and Experimental Myasthenia Gravis

Overview
Specialty Science
Date 1982 Aug 1
PMID 6181515
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

trans-3,3'-Bis[alpha-(trimethylammonio)methyl]azobenzene bromide (BisQ) is a potent agonist of the acetylcholine receptor (AcChoR) of Electrophorus electricus. BisQ is highly constrained, suggesting that its structure is complementary to the combining site of the AcChoR when the latter is in its activated state. Antibodies produced in rabbits to a conjugate of bovine serum albumin and a derivative of BisQ mimicked the binding characteristics of the AcChoR with respect to the order of binding of a variety of agonists and to the preferred recognition of decamethonium ion (an agonist) over hexamethonium ion (an antagonist). Immunization of three rabbits with purified anti-BisQ yielded antisera having binding characteristics of anti-AcChoR in that, by complement fixation and enzyme immunoassay, crossreactions with receptor preparations from rat, Torpedo, and eel could be demonstrated in sera of all three rabbits immunized. Two of the three rabbits showed signs of muscle weakness similar to that seen after immunization with the AcChoR. One of the rabbits was injected intramuscularly with neostigmine and showed temporary improvement. Another showed post-tetanic exhaustion of hind-limb muscles after stimulation of the sciatic nerve at 50 Hz. Antibodies reactive with the AcChoR, therefore, were elicited by immunization with an antibody to a potent ligand of the AcChoR without the necessity of isolating the receptor itself. A similar mechanism may play a part in the etiology of at least some autoimmune diseases in which antibodies to various other receptors are involved.

Citing Articles

Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies.

Bellucci M, Bozzano F, Castellano C, Pesce G, Beronio A, Farshchi A Front Immunol. 2024; 15:1398028.

PMID: 39148725 PMC: 11324485. DOI: 10.3389/fimmu.2024.1398028.


High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Cleveland W, DeLaPaz R, Fawwaz R, Challop R Neural Plast. 2010; 2009:768398.

PMID: 20182547 PMC: 2825652. DOI: 10.1155/2009/768398.


Putative receptor for the plant growth hormone auxin identified and characterized by anti-idiotypic antibodies.

Prasad P, Jones A Proc Natl Acad Sci U S A. 1991; 88(13):5479-83.

PMID: 11607194 PMC: 51900. DOI: 10.1073/pnas.88.13.5479.


Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum.

Su S, Yang S, Ding R, Davidson E Infect Immun. 1996; 64(1):326-31.

PMID: 8557359 PMC: 173763. DOI: 10.1128/iai.64.1.326-331.1996.


Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Graus Y, De Baets M Immunol Res. 1993; 12(1):78-100.

PMID: 7685805 DOI: 10.1007/BF02918370.


References
1.
Erlanger B . Principles and methods for the preparation of drug protein conjugates for immunological studies. Pharmacol Rev. 1973; 25(2):271-80. View

2.
Karlin A . The acetylcholine receptor: progress report. Life Sci. 1974; 14(8):1385-415. DOI: 10.1016/0024-3205(74)90150-7. View

3.
Smith B, Hall R . Thyroid-stimulating immunoglobulins in Graves' disease. Lancet. 1974; 2(7878):427-31. DOI: 10.1016/s0140-6736(74)91815-7. View

4.
Brockes J, Hall Z . Acetylcholine receptors in normal and denervated rat diaphragm muscle. I. Purification and interaction with [125I]-alpha-bungarotoxin. Biochemistry. 1975; 14(10):2092-9. DOI: 10.1021/bi00681a008. View

5.
Flier J, Kahn C, Roth J, Bar R . Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science. 1975; 190(4209):63-5. DOI: 10.1126/science.170678. View